Literature DB >> 712117

Antigenic drift and efficacy of influenza virus vaccines, 1976--1977.

G Meiklejohn, T C Eickhoff, P Graves, J I.   

Abstract

A unique opportunity occurred in February 1977 to assess the efficacy of an influenza virus vaccine given to military personnel in doses of 400 chick cell-agglutinating (CCA) units of A/Victoria/3/75, 400 CCA units of A/New Jersey/76, and 500 CCA units of B/Hong Kong/72 viruses. After cessation of all influenza virus vaccine administration in mid-December 1976, approximately 200 unvaccinated U.S. Air Force personnel arrived per week beginning February 1, 1977, at Lowry Air Force Base, Denver, Colorado. Arriving unvaccinated personnel were assigned to one of 12 units with previously vaccinated personnel. A sharp outbreak of influenza A occurred on the base during February that was due to an A/Texas/1/77-like virus, a variant of the A/Victoria/3/75 prototpye. Fifty-four cases of influenza A were documented in the student population on the base. During the two-week peak of the outbreak, attack rates were 10-fold higher in unvaccinated than in vaccinated students, and the overall estimate of vaccine efficacy was 80%. Thus, despite animal tests suggesting considerable antigenic drift, a vaccine containing influenza A/Victoria/3/75 virus provided good protection against the variant strain.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 712117     DOI: 10.1093/infdis/138.5.618

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company.

Authors:  E Burckel; T Ashraf; J P de Sousa Filho; E Forleo Neto; H Guarino; C Yauti; B Barreto F de; L Champion
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 2.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Current concepts of control measures for influenza.

Authors:  R Dolin
Journal:  Trans Am Clin Climatol Assoc       Date:  1990

4.  Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic.

Authors:  N Arden; A S Monto; S E Ohmit
Journal:  Am J Public Health       Date:  1995-03       Impact factor: 9.308

Review 5.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 6.  Does influenza vaccination exacerbate asthma?

Authors:  C L Park; A Frank
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

7.  The human cytotoxic T cell response to influenza A vaccination.

Authors:  A J McMichael; F Gotch; P Cullen; B Askonas; R G Webster
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

8.  Protection by a polyvalent influenza vaccine and persistence of homologous and heterologous HI antibodies during a period of two epidemic seasons.

Authors:  R Pyhälä
Journal:  J Hyg (Lond)       Date:  1980-04

9.  Relationship between surface antigens of two variants of influenza A (H3N2) virus, as revealed by hemagglutination inhibition, kinetic neutralization, and neuraminidase inhibition.

Authors:  C N Hsia; H M Foy; M K Cooney
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

10.  Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.

Authors:  Zuzana Biesova; Mark A Miller; Rachel Schneerson; Joseph Shiloach; Kim Y Green; John B Robbins; Jerry M Keith
Journal:  Vaccine       Date:  2009-08-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.